好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Treatment Adherence, Persistence, and Compliance at 96 Weeks in MS Patients Using RebiSmart® for Injection of Interferon β-1a
Multiple Sclerosis
(-)
037
Authors/Disclosures
Virginia A. Devonshire, MD (UBC Hospital S126)
PRESENTER
Dr. Devonshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck- Serono. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Devonshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen . Dr. Devonshire has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for novartis. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for roche. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for biogen .
Anthony Feinstein, MD (Sunnybrook Health Sciences Centre) Anthony Feinstein, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis, Biogen, Roche and Sanofi-Genzyme. The institution of Anthony Feinstein, MD has received research support from Multiple Sclerosis Society of Canada. Anthony Feinstein, MD has received publishing royalties from a publication relating to health care.
Alan Gillett, PhD (Merck) No disclosure on file